301080 Acrobiosystems
- 37.60
- +2.55+7.28%
Acrobiosystems News
Baipu Science (301080.SZ): The company is building an AI technology application platform, which will be applied to the transformation process of proteins.
On August 15th, Gelonghui reported that Baipu Saishi (301080.SZ) on the investor interaction platform stated that AI technology, with its powerful data processing and analysis capabilities, is gradually changing the research and development process of the innovative drug industry. Currently, the company is building an AI technology application platform and applying the technology to the protein modification process. Through collaborative AI calculation and simulation of "dry experiments" and high-throughput "wet experiments," AI technology is combined with computationally based virtual screening methods, continuously closed, and iterated to ultimately obtain specific proteins. Taking universal nucleases as an example, it is essentially a protein, in order to meet.
Is AcrobiosystemsLtd (SZSE:301080) Using Too Much Debt?
ACROBiosystems Launches GMP Brand Resilient Supply at ISSCR to Accelerate Cell and Gene Therapy Development
Baipusi (301080.SZ) plans to distribute 9 yuan per 10 shares, with ex-rights and ex-dividends on July 5.
Baipu Saisi (301080.SZ) announced that the company plans to distribute annual equity dividends in 2023, with a distribution of 1.0 yuan (tax included) for every 10 shares to all shareholders.
Express News | Syntekabio Signs Memorandum of Understanding With Bioseedin/Acrobiosystems
Acrobiosystems Co.,Ltd.'s (SZSE:301080) Most Bullish Insider, CEO Yiding Chen Must Be Pleased With the Recent 10% Gain
Pepsis (301080.SZ): Net profit of 306.721 million yuan in the first quarter decreased by 31.91% year-on-year
On April 23, GLONGHUI (301080.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 146 million yuan, up 6.67% year on year; net profit attributable to shareholders of listed companies was 306.721 million yuan, down 31.91% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 30.2819 million yuan, down 32.12% year on year; basic earnings per share were 0.2561 yuan.
ACROBiosystems Lanza Soluciones Organoides 3D, Impulsando Nuevas Fronteras En La Investigación Bioterapéutica
ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research
Acrobiosystems Co.,Ltd.'s (SZSE:301080) Intrinsic Value Is Potentially 18% Below Its Share Price
ACROBiosystems Launches New Initiative to Support Cell and Gene Manufacturers
Acrobiosystems Co.,Ltd. (SZSE:301080) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Pepsis (301080.SZ): The repurchase was completed, and the total cost was 16.11 million yuan to repurchase 273,800 shares
Glonghui, January 18, 丨 Baipsis (301080.SZ) announced that as of January 17, 2024, the company had repurchased 273,800 shares through a dedicated stock repurchase securities account, accounting for 0.2282% of the company's total share capital. The highest transaction price was 67.60 yuan/share, the minimum transaction price was 51.22 yuan/share, and the total transaction amount was 16.11 million yuan (excluding transaction fees). The actual share repurchase period is August 11, 2023 to January 17, 2024. .
Bepsis (301080.SZ): In terms of gene editing, the company launched CAS series proteins including CAS9 and Cas12a
On January 9, GLONGHUI (301080.SZ) said on the investor interactive platform that the company focuses on drug development and application scenarios, and continues to launch high-quality, high-batch-stable products for use in drug development and production processes based on a deep understanding of biopharmaceuticals, cell and gene therapy R&D and production. In terms of gene editing, the company launched CAS series proteins, including CAS9 and Cas12a, which are mainly used for targeted gene editing, etc., to provide high editing efficiency.
Bepsis (301080.SZ): The main products and services are used in drug development and production processes for diseases such as tumors, autoimmune diseases, cardiovascular diseases, infectious diseases, etc.
On January 9, GLONGHUI (301080.SZ) said on the investor interactive platform that the company is a high-tech enterprise specializing in providing key biological reagents and technical services such as recombinant proteins and antibodies. The main products and services are used in drug development and production for diseases such as tumors, autoimmune diseases, cardiovascular diseases, and infectious diseases.
Pepsis (301080.SZ): A total cost of 9.9983 million yuan to buy back 161,600 shares
On January 3, GLONGHUI (301080.SZ) announced that as of December 31, 2023, the company had repurchased a total of 161,600 shares through a special stock repurchase securities account, accounting for 0.1347% of the company's total share capital. The highest transaction price was 67.60 yuan/share, the minimum transaction price was 57.30 yuan/share, and the total transaction amount was 9.9983 million yuan (excluding transaction fees).
Following Recent Decline, Acrobiosystems Co.,Ltd.'s (SZSE:301080) Top Shareholder CEO Yiding Chen Sees Holdings Value Drop by 5.2%
Bypsyth (301080.SZ): Repurchased 45,000 shares at a total cost of 2.98 million yuan
Glonghui (301080.SZ) announced on December 5, 2023, that as of November 30, 2023, the company has repurchased a total of 45,000 shares through centralized bidding transactions through a special stock repurchase account, accounting for 0.0375% of the company's total share capital. The highest transaction price is 67.60 yuan/share, the lowest transaction price is 63.96 yuan/share, and the total transaction amount is 2,981,029.00 yuan.
Bypsyth (301080.SZ) granted 1,308.97 million restricted shares at a price of 33.58 yuan/share
Bypsyth (301080.SZ) announced that the restricted shares stipulated in the company's 2023 restricted stock incentive plan...
Capital Securities: Biomedical investment and financing have shown signs of steady recovery, and the performance of some companies is expected to reach an inflection point in 2024
With the resumption of investment and financing in the global biomedical industry's primary market, especially overseas markets, the performance of some companies is expected to reach an inflection point in 2024.
Analysis
Price Target
No Data
